—EMR
— • —
$143.77
P/E
35.14
PEG
—
FCF Yield
—
Rev Growth YoY
+362.0% YoY
Gross Margin
5275.0%
Health Score
5/10
D/E Ratio
0.65
Confidence
LOW
Business Snapshot
The ticker and exchange identifiers are absent from this payload, which limits company-specific context. Based on the available financial profile — a current price of $143.77, a P/E of 35.14x, and revenue growth of 362% year-over-year — this appears to be a high-growth company in an early or expansion phase. Without a confirmed market capitalisation figure, cap-tier classification cannot be made with precision.
Financial Health
**Score: 5/10** The company's margin profile is extraordinary on its face — a gross margin of 5,275% and a net margin of 1,271% — but these figures are so anomalous that they likely reflect accounting peculiarities, asset revaluations, or one-time items rather than sustainable operational performance, and should be interpreted with significant caution. Debt appears manageable with a Debt/Equity ratio of 0.65x, which is below typical stress thresholds...
Risk Assessment
- **DATA QUALITY: Gross margin of 5,275% and net margin of 1,271% are statistically implausible for normal operations** and may indicate data errors, one-time items, or non-standard reporting — investors must verify independently. - **EARNINGS DETERIORATION: Earnings growth of -273% YoY directly contradicts the strong revenue acceleration,** suggesting the company is not converting top-line gains into bottom-line results. - **LIQUIDITY: Current ratio of 0.88x means current liabilities exceed current assets,** indicating potential short-term cash pressure. - **VALUATION PREMIUM: P/E of 35.14x is approximately 41% above the sector average of 25x** with no DCF estimate or PEG ratio available to justify the premium. - **TECHNICAL WEAKNESS: A death cross pattern is confirmed (50-day MA below 200-day MA),** with MACD on a bearish signal — both are classically negative momentum indicators. ---...